Roca i Martínez J, Durán Bellido M, Suris i Granell J C, Iglesias Salvador D, Hidalgo Ibáñez M J, Juncosa Morros T, Latorre Otín C
Servicio de Pediatría, Hospital Infantil San Juan de Dios, Barcelona.
An Esp Pediatr. 1990 Jan;32(1):53-7.
Fifty-eight paediatric patients aged one month to 14 years, who met the inclusion criteria for urinary infection, were studied. They were administered amox/clav at a dose of 21.9 +/- 2.96 (mean +/- SD) mg/kg/day for ten days. E. coli was isolated in 53 cases, P. mirabilis in two, K. pneumoniae in two and E. cloacae in one. Of the E. coli, 94.34% were sensitive to amox/clav, 67.92% were resistant to ampicillin, three cases showed intermediate sensitivity and the case of E. cloacae was resistant. These four patients were withdrawn from the study, and four more who did not come for follow-up. Of the 50 assessable patients, 94% were cured. Three days after completing the treatment, three patients (6%) still had a positive uroculture, although only one showed symptoms. Of the remaining 47, five cases (11%) presented bacteriological relapse in the culture made seven days later. Only 10% of the patients showed any type of gastrointestinal disturbances, and interruption of treatment was not necessary. The amox/clav combination, in view of its broad spectrum, easy administration by oral route and good tolerance, should be taken into account as a first choice treatment in urinary infections in paediatric patients of any age.
对58例年龄在1个月至14岁之间符合泌尿道感染纳入标准的儿科患者进行了研究。他们接受阿莫西林/克拉维酸治疗,剂量为21.9±2.96(均值±标准差)mg/kg/天,持续10天。分离出大肠杆菌53例、奇异变形杆菌2例、肺炎克雷伯菌2例、阴沟肠杆菌1例。在大肠杆菌中,94.34%对阿莫西林/克拉维酸敏感,67.92%对氨苄西林耐药,3例显示中度敏感,阴沟肠杆菌病例耐药。这4例患者退出研究,另有4例未前来随访。在50例可评估患者中,94%治愈。完成治疗3天后,3例患者(6%)尿培养仍为阳性,尽管只有1例有症状。在其余47例中,5例(11%)在7天后进行的培养中出现细菌学复发。只有10%的患者出现任何类型的胃肠道不适,无需中断治疗。鉴于阿莫西林/克拉维酸联合用药具有广谱、易于口服给药和耐受性良好的特点,应考虑作为任何年龄儿科患者泌尿道感染的首选治疗药物。